Ciprotab, Cipronol and Ciprofloxacin are different names given by companies to the same drug called Ciprofloxacin. Ciprofloxacin is a strong antibiotic.
Ciprofloxacin belongs to a class/type of a drug called fluoroquinolone
Warnings for ciprofloxacin and other fluoroquinolone antibiotics have been updated by the U.S. Food and Drug Administration. This update is due to the disabling and potentially permanent side effects associated with their use. The risks and benefits should be considered very carefully by both health care providers and patients before making an informed decision on their use. No doubt, fluoroquinolones (Ciproflocaxin and related drugs) are effective in treating serious bacterial infections, but an FDA safety review found that both oral and injectable fluoroquinolones are associated with disabling side effects involving tendons, muscles, joints, nerves and the central nervous system which can occur hours to weeks after exposure to fluoroquinlones and may potentially be permanent.
Do not start using Ciprotab or related drugs whenever you feel you’ve treated malaria and symptoms persist – it could be very dangerous. Seek medical attention instead.
Thus, the recommendation is that the use of this drug should be limited in people with less serious infections i.e. Ciprotab and related drugs should not always be the drug to use whenever there are symptoms suggestive of a bacterial infection – especially if the infection is less serious.
In persons with less serious bacterial infections (such as uncomplicated urinary tract infections, acute bacterial sinusitis), the risk of serious effects far outweighs the benefits and so alternative treatment options, if available, are appropriate. But, for serious bacterial infections (such as bacterial pneumonia), the benefits far outweigh the risk and is appropriate that it remains available as a therapeutic option.
Ciprofloxacin and other fluoroquinolone antibiotics are reserved for serious bacterial infections (benefits outweigh the risks)
To be used in less serious bacterial infections if there’re no other available treatment options (risks outweigh the benefits)
Related researchMandell and Tillotson (2002), in The Canadian Journal of Infectious Diseases:
Levofloxacin, have been observed to induce a range of CNS-related adverse reactions, including headaches (9% ofloxacin, 6% levo-floxacin), dizziness (5% ofloxacin, 3% levofloxacin), and less common events include confusion, impaired thinking, insomnia and rarely psychosis. Photoallergic reactions and phototoxic responses are also reported side effects. Other reported side effects include anaphylaxis, hepatic reactions (trovafloxacin) and severe cutaneous rashes.
Strauchman and Morningstar (2012) in Clinics and Practice: Fluoroquinolone medications have been shown to contribute to tendinopathies, cardiotoxicity, and neurotoxicity.